Gary Nachman

Mallinckrodt Eyes Restructuring Ahead Of Cleveland Opioid Trial: 'Bankruptcy A Real Option'

BMO Says 'Questions Still Remain' About Lannett Following Earnings Pop

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

BMO Says 'Questions Still Remain' About Lannett Following Earnings Pop

Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade

Aptinyx Represents Untapped Value, BMO Says

BMO Sees Compelling Valuation For Trevi Therapeutics At Current Levels

Aptinyx Represents Untapped Value, BMO Says

BMO Sees Compelling Valuation For Trevi Therapeutics At Current Levels

Mallinckrodt Slumps After Filing Acthar Lawsuit, But BMO Says It Can Take The Hit

Mylan's Disappointing Outlook Rattles Analysts, Investors

Gary Nachman Recent News

BMO Capital Markets: Lannett Making Progress With Pipeline, Cost Savings

BMO Smells Opportunity In OptiNose

Flexion Therapeutics Just Hit A Major Milestone

Valeant Expresses Confidence In Outlook, But Might Be Too Early To Get Bullish

Pershing Square's Valeant Sale Sends 'Untimely Poor Signal'

Analysts Having Difficulty Getting Comfortable With Valeant's Fundamentals

Mallinckrodt Nuclear Biz Sale A Positive In BMO's View, Maintains Outperform

Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines

Pacira Shares Tumble Following BMO's New Underperform Rating

4 Reasons To Own Horizon Pharma Shares

BMO Starts Valeant At Market Perform On Debt Burden, Execution Uncertainty

Goldman Downgrades Valeant, Sees 'Long Road' For Controversial Stock

Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel

Leerink Swann Lowers Sucampo Pharmaceuticals (SCMP) Valuation To $6 - $7

Valeant Pharmaceuticals International’s (VRX) Fourth-Quarter Review